Sodium glucose transporter 2 (SGLT2) inhibitors added to insulin therapy in type 2 diabetes (T2DM), have shown renoprotective and therapeutic effects on decreasing glycated hemoglobin (HbA1C), required insulin dosage, glucose intolerance, and body‐weight.1, 2, 3. This evidence concerns the gene INS and type 2 diabetes mellitus.